FilingReader Intelligence

Boya Bio lands partial land storage deal amidst growth

April 25, 2025 at 05:26 AM UTC•By FilingReader AI

Boya Bio-Pharmaceutical Group (SZSE:300294) reported a 19.49% year-over-year increase in revenue to CNY535.88 million for the first quarter of 2025, primarily driven by its acquisition of Green Cross. The company's core blood product business saw stable growth, bolstered by increased sales of albumin and intravenous immunoglobulin.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

Primary Source Document

Announcement on the acquisition of part of the land for the project to be invested by the raised fundsApril 24, 2025 at 08:00 AM UTC

Supplementary Source Documents

Announcement on the acquisition of part of the land for the project to be invested by the raised fundsApril 24, 2025 at 10:19 AM UTC

Boya Bio-Pharmaceutical Group

SZSE:300294•Shenzhen Stock Exchange

Pharmaceuticals

RSS feed for Boya Bio-Pharmaceutical Group

News Alerts

Get instant email alerts when Boya Bio-Pharmaceutical Group publishes news

Free account required • Unsubscribe anytime

Browse RSS Feeds

Filing Activity Timeline

View Complete Filing History →